Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01029704 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT01029704: Completed Phase 2 study, sponsored by Theracos.
NCT01029704 is a Phase 2 study that has completed, run by Theracos. The registered enrollment target is 151 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01029704, a Phase 2 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes. The study also assessed the pharmacokinetics, safety and tolerability of EGT0001442, the effect on weight and HbA1c as well as the effect EGT0001442 has on the amount of glucose produced in the body by the urine.
Primary Outcome
Fasting glucose levels were measured at four time points; At day -2, day 1, day 27 and day 29 (24-h after the last dose). Baseline is defined as the mean of FPG values on day -2 and day 1. End of treatment is defined as the mean of FPG values on day 27 and day 29. Changes in the FPG during the study period was calculated by subtracting the Baseline FPG from End of Treatment FPG.
Interventions
- DRUG EGT0001442
- DRUG Placebo capsules to match EGT0001442
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
What the finished NCT01029704 record still lists
NCT01029704 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 2 interventions - of which EGT0001442 is the first listed.
NCT01029704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01029704 about?
NCT01029704 is a clinical study titled "Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus". The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes. The study also assessed the pharmacokinetics, safety and tolerability of EGT0001442, the effect on weight and HbA1c as well as the effect EGT000144...
What is the current status of trial NCT01029704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2009-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01029704?
The interventions under investigation include: EGT0001442 (DRUG), Placebo capsules to match EGT0001442 (DRUG).
Who is sponsoring clinical trial NCT01029704?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01029704's enrollment target sits among peer trials
151 454th of 2000 higher than 1,546 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia